Payment overview · 2025
General Payments
$90.23
6 reported records · 4 companies
Healthcare provider profile · identity verified
Heath Eggleston
Allopathic & Osteopathic Physicians|Family Medicine · SPEARFISH, SD · NPI 1376988147
Verified facts
What the public records show
CMS Open Payments records show Heath Eggleston received $90.23 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.09 | 37.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.15 | 31.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 15.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 15.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.23 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 562 | 143 |
| Omeprazole | Omeprazole | 450 | 122 |
| Losartan Potassium | Losartan Potassium | 419 | 115 |
| Lisinopril | Lisinopril | 413 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 103 |
| Metformin Hcl | Metformin Hcl | 290 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 64 |
| Simvastatin | Simvastatin | 216 | 60 |
| Trazodone Hcl | Trazodone Hcl | 212 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 60 |
| Gabapentin | Gabapentin | 190 | 53 |
| Potassium Chloride | Potassium Chloride | 188 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 50 |
| Allopurinol | Allopurinol | 174 | 47 |
| Furosemide | Furosemide | 153 | 48 |
| Sertraline Hcl | Sertraline Hcl | 139 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 32 |
| Bupropion Xl | Bupropion Hcl | 129 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 30 |
| Tramadol Hcl | Tramadol Hcl | 124 | 33 |
| Eliquis | Apixaban | 122 | 32 |
| Prednisone | Prednisone | 118 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 33 |
| Montelukast Sodium | Montelukast Sodium | 105 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 26 |
| Alprazolam | Alprazolam | 99 | 19 |
| Warfarin Sodium | Warfarin Sodium | 97 | 21 |
| Synthroid | Levothyroxine Sodium | 94 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 31 |
| Baclofen | Baclofen | 83 | 23 |
| Ozempic | Semaglutide | 83 | 19 |
| Clonazepam | Clonazepam | 81 | 16 |
| Mounjaro | Tirzepatide | 78 | 12 |
| Finasteride | Finasteride | 76 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 18 |
| Lorazepam | Lorazepam | 75 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 19 |
| Famotidine | Famotidine | 69 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Atenolol | Atenolol | 66 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 21 |
| Carvedilol | Carvedilol | 64 | 18 |
| Donepezil Hcl | Donepezil Hcl | 64 | 12 |
| Pregabalin | Pregabalin | 64 | 11 |
| Ezetimibe | Ezetimibe | 62 | 19 |
| Spironolactone | Spironolactone | 61 | 19 |
| Amoxicillin | Amoxicillin | 60 | 42 |
| Metformin Hcl Er | Metformin Hcl | 59 | 17 |
| Xarelto | Rivaroxaban | 59 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Jardiance | Empagliflozin | 46 | 13 |
| Diazepam | Diazepam | 45 | 11 |
| Meloxicam | Meloxicam | 44 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 35 |
| Buspirone Hcl | Buspirone Hcl | 41 | 15 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 35 | suppressed |
| Azithromycin | Azithromycin | 35 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 11 |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 15 |
| Lactulose | Lactulose | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Sucralfate | Sucralfate | 17 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.23 · 6 records | PFIZER INC. | ABRYSVO, COMIRNATY, JARDIANCE, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error